Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENT-1: Repotrectinib in Advanced Solid Tumors
NCT03093116Phase 2Recruiting
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Mar 2017
- Primary completion
- Feb 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 19
01
Overview
A Phase 2 trial of repotrectinib in solid tumor, non-small cell lung cancer (NSCLC), sponsored by Turning Point Therapeutics, Inc.. Started Mar 2017; status: recruiting.
02
Drugs
repotrectinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03093116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093116.